Vipivotide tetraxetan

SKU: orb1309212

Description

Vipivotide tetraxetan (PSMA-617) is a small molecule inhibitor with high potency for prostate-specific membrane antigen, exhibiting a Ki of 0.37 nM. It is widely used in preclinical research, including in vitro binding assays and in vivo theranostic studies for prostate cancer, leveraging its targeting for imaging and therapeutic applications.

Research Area

Immunology & Inflammation

Key Properties

• CAS Number: 1702967-37-0
• MW: 1042.14
• Purity: 100.00% (May vary between batches)
• Formula: C₄₉H₇₁N₉O₁₆
• SMILES: OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@H]1CC[C@H](CNC(=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)CC1)C(O)=O)C(O)=O
• Target: PSMA|||Drug-Linker Conjugates for ADC
• Solubility: DMSO:100 mg/mL (95.96 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (3.84 mM);H2O:100 mg/mL (95.96 mM)

Bioactivity

• Target IC50:
  PSMA:0.37 nM (Ki)|LNCaP cells:2.34 - 2.94 nM (Ki)
• In Vivo:
  The small-animal PET measurements showed high tumor-to-background contrasts as early as 1 h after injection of Vipivotide tetraxetan.Organ distribution revealed specific uptake in LNCaP tumors and in the kidneys 1 h after injection of Vipivotide tetraxetan.
  Read more...
• In Vitro:
  The chemically modified PSMA inhibitor PSMA-617 demonstrated high radiolytic stability for at least 72 h. A high inhibition potency (equilibrium dissociation constant [K(i)] = 2.34 2.94 nM on LNCaP; K(i) = 0.37 0.21 nM enzymatically determined) and highly efficient internalization into LNCaP cells were demonstrated.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Drug-Linker Conjugates for ADC, DrugLinker Conjugates for ADC, DrugLinkerConjugatesforADC, ADC Linker, inhibit, Inhibitor, PSMA 617, PSMA617, PSMA-617, Vipivotide tetraxetan

Compound Identifiers

PubChem CID

122706786